Virovek, Inc.

Virovek specializes in customized and large-scale AAV (adeno-associated virus) production through our innovative and patented BAC-to-AAV and toxin-based cell ablation technologies. Our AAV production platform is able to accommodate any AAV serotype, generate 1E+17 vg/mL of purified virus from a single production run, with typical viral titers between 2 to 2.50E+13 vg/mL, and can be further concentrated to 1E+14 vg/mL. We offer comprehensive services include gene cloning and baculovirus production. A large scale AAV production service using 293 mammalian cells is under development, with pending patents. All of our proprietary technologies are available for non-exclusive licensing. Since 2006, Virovek has produced thousands of AAV vectors at >1E+13vg/mL scale to support research projects in over 100 university laboratories, non-profit institutions, and industry leaders worldwide. Our customer base spans across the Americas and Eurasia, and we are actively seeking partnership with institutions in Africa and Oceania. Visit us at www.virovek.com, get a quote or make an inquiry today!

网站

http://www.virovek.com

Virovek, Inc.的外部链接

所属行业

生物技术研究

规模

11-50 人

总部

Houston，Texas

类型

私人持股

创立

2006

领域

Large scale AAV production in Sf9 cells、Bac-to-AAV Technology (patent granted)、Research and Development、Biotechnology Laboratories、Pre-GMP、Gene Therapy、Production and Manufacturing、Gene Cloning、Assays和Adeno-Associated Virus